Monoject Prefill Flush Syringe 의 안전성 경고

Department of Health에 따르면, 해당 안전성 경고 는 Hong Kong 에서 Covidien 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

안전성 경고는 의료기기 제품과 관련된 중요한 정보와 권고사항을 담고 있습니다. 물론 안전성 경고가 배포되었다고 해서 해당 제품이 무조건 안전하지 않은 제품이라는 것은 아닙니다. 보건의료업계 종사자와 의료기기 사용자들에게 배포되는 안전성 경고에는 회수(recall)도 포함될 수 있습니다. 제조사가 안전성 경고를 작성하기도 하지만, 보건당국에서 작성하는 경우도 있습니다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Safety alert
  • 날짜
    2013-08-20
  • 사례 출판 날짜
    2013-08-20
  • 사례 국가
  • 사례 출처
    DH
  • 사례 출처 URL
  • 비고 / 경고
    Hong Kong data is current through September 2018. All of the data comes from the Department of Health (Hong Kong), except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Hong Kong.
  • 데이터 추가 비고
    Medical Device Safety Alert
  • 원인
    Medical device safety alert: covidien monoject prefill flush syringe the united states food and drug administration (fda) has posted a press release issued by covidien concerning a voluntary recall of certain lots of monoject prefill flush syringes. the affected products are identified as follow:- monoject 0.9% sodium chloride flush syringe, 12 ml syringe with 10 ml fill product id: 8881570121 lot number: 13a0084n, 13a0094, 13b0364, 13c0504, 13c0514 monoject 0.9% sodium chloride flush syringe, 12 ml syringe with 3 ml fill product id: 8881570123 lot number: 13a0084n monoject 0.9% sodium chloride flush syringe, 12 ml syringe with 5 ml fill product id: 8881570125 lot number: 13a0084n monoject 10 units/ml heparin lock flush, 12 ml syringe with 10 ml fill product id: 8881580121 lot number: 13a0084n monoject 10 units/ml heparin lock flush, 12 ml syringe with 3 ml fill product id: 8881580123 lot number: 13a0084n monoject 10 units/ml heparin lock flush, 12 ml syringe with 5 ml fill product id: 8881580125 lot number: 13a0084n monoject 100 units/ml heparin lock flush, 12 ml syringe with 10 ml fill product id: 8881590121 lot number: 13a0084n monoject 100 units/ml heparin lock flush, 12 ml syringe with 3 ml fill product id: 8881590123 lot number: 13a0084n monoject 100 units/ml heparin lock flush, 12 ml syringe with 5 ml fill product id: 8881590125 lot number: 13a0084n, 13d0824n the recall is being conducted due to the risk that a number of the syringes were filled with water but not subjected to the autoclave sterilization process. these products are labeled as either sodium chloride flush or heparin lock flush. some of these syringes have the mismatched syringe tip cap, syringe label, filled volume and wrapper. however, for the sodium chloride flush syringes with matched tip cap, syringe label, filled volume and wrapper, there are no visual cues for the clinician to identify the problematic products. if non-sterile fluid is administered there is a health risk of life-threatening infection to the blood stream or other areas. besides, if the clinician uses the heparin lock flush syringe containing only water on peripheral or venous catheters, the patency of the intravascular device may not be maintained and clotting may occur. this could result in non-functional intravenous access requiring the device to be replaced the affected users are required to identify, segregate and return any affected products in their inventory. according to the local supplier, the affected products were not distributed in hong kong. for details, please visit the following fda website: http://www.Fda.Gov/safety/recalls/ucm365577.Htm if you are in possession of the affected products, please contact your supplier for necessary actions. posted on 20 august 2013.

Device

  • 모델명 / 제조번호(시리얼번호)
  • 제품 설명
    Medical Device Safety Alert: Covidien Monoject Prefill Flush Syringe
  • Manufacturer

Manufacturer

  • 제조사 모회사 (2017)
  • 제조사 의견
    “If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.
  • Source
    DH